TINAGL1 Inhibitors
Chemical inhibitors of TINAGL1 function by impeding various pathways and enzymatic activities that are essential for the protein synthesis within cells. Rapamycin and its derivatives, including Sirolimus, Everolimus, and Temsirolimus, directly target the mTOR pathway, a pivotal regulator of protein translation. These inhibitors bind to the mTOR complex, which leads to a reduction in its kinase activity. As a result, the downstream effectors of mTOR, critical for the initiation and progression of protein synthesis, are less active, leading to a decrease in the cellular production of proteins such as TINAGL1. Similarly, Palomid 529 and the ATP-competitive inhibitors PP242, Torin 1, and AZD8055 also inhibit the mTOR signaling but with varying specificities and potencies. These molecules are designed to either bind to different domains of the mTOR kinase or affect both mTOR complexes (mTORC1 and mTORC2), ultimately curtailing the protein's synthesis at the translational level.
In parallel, LY294002 and Wortmannin exert their inhibitory action upstream of mTOR, targeting the PI3K/AKT pathway. By inhibiting PI3K, these compounds reduce AKT phosphorylation and activity, which consequently leads to diminished activation of mTOR and a subsequent decrease in protein synthesis, affecting the production of TINAGL1. Spautin-1, on the other hand, works by promoting the degradation of proteins associated with the PI3K/AKT/mTOR pathway through the inhibition of ubiquitin-specific proteases. This action not only decreases the levels of key signaling molecules within the pathway but also increases the turnover of existing proteins, which includes TINAGL1. KU-0063794 specifically suppresses both mTORC1 and mTORC2 complexes, leading to a reduction in the overall mTOR signaling.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR (mammalian target of rapamycin), which is a crucial regulator of cell growth and protein synthesis. Inhibition of mTOR can lead to reduced protein translation and potentially decrease the synthesis of TINAGL1 due to lower general protein synthesis capabilities within the cell. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K (phosphoinositide 3-kinases). By inhibiting PI3K, it impedes the PI3K/AKT/mTOR signaling pathway, which is involved in cell growth and survival. The subsequent downregulation of this pathway can reduce the synthesis of proteins, including TINAGL1, due to diminished translational activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor, which, similar to LY294002, leads to reduced activity of the AKT/mTOR pathway. This can lead to a decrease in the cellular processes that are responsible for the synthesis of various proteins, including potentially TINAGL1, due to the importance of this pathway in regulating protein synthesis. | ||||||
Spautin-1 | 1262888-28-7 | sc-507306 | 10 mg | $168.00 | ||
Spautin-1 is known to promote the degradation of PI3K/AKT/mTOR pathway components by inhibiting ubiquitin-specific peptidases USP10 and USP13. This can lead to a decrease in TINAGL1 levels as the general protein turnover is increased, thereby reducing the stability and presence of cellular proteins. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
Palomid 529 (P529) inhibits both the mTORC1 and mTORC2 complexes of the mTOR pathway, which can result in decreased protein synthesis. This broad inhibition may lead to the functional inhibition of TINAGL1 protein synthesis in cells due to the reduced activity of these complexes that are critical for protein production. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is a derivative of sirolimus and works as an mTOR inhibitor. It can decrease the protein synthesis of cells, and thus potentially inhibit the synthesis of TINAGL1, by impairing the function of the mTOR pathway which is critical for cell growth and protein production. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is a selective inhibitor of mTOR kinase activity, which inhibits both mTORC1 and mTORC2. This inhibition can lead to a decrease in protein synthesis within the cell, potentially affecting the synthesis of TINAGL1 by reducing the translation of proteins. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is a potent and selective mTOR inhibitor that can lead to a decrease in cell growth and protein synthesis, potentially inhibiting the synthesis of TINAGL1 by reducing the overall mTOR pathway activity which is integral for protein production. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an ATP-competitive inhibitor of mTOR kinase, which inhibits both mTORC1 and mTORC2 complexes. This inhibition may result in decreased synthesis of various proteins, including TINAGL1, due to the diminished activity of the mTOR pathway which is essential for protein synthesis. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
KU-0063794 is a selective mTOR inhibitor that can suppress mTORC1 and mTORC2 activation. This suppression may lead to decreased protein synthesis in the cell, potentially inhibiting the production of TINAGL1 by affecting the mTOR signaling pathway which regulates protein translation. | ||||||